Synlogic stock.

We are driven by the promise of synthetic biology and by the new possibilities for better health that we believe we can bring to patients. Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease.Find out all the key statistics for Synlogic, Inc. (SYBX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.Concurrently with the execution of the Merger Agreement, certain officers, directors and stockholders of Mirna holding approximately 32% of the outstanding Mirna common stock and certain officers, directors and stockholders of Synlogic holding approximately 84% of the Synlogic capital stock (giving effect to Synlogic’s recent Series C financing) have …Mar 8, 2023 · CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B ...

Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.

Jun 30, 2023 · Second Quarter 2023 Financial Results and Financial Outlook. As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research ...

Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic ...SYBX Stock 12 Months Forecast. $21.67. (983.50% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $21.67 with a high forecast of $35.00 and a low forecast of $6.00. The average price target represents a 983.50% change from the last price of $2.00.Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering. Sep. 29. AQ. Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism. Sep. 28. AQ. Phenylketonuria Pipeline, Emerging Drugs, Clinical Trials, and FDA Approvals 2023 (Updated) Sep. 28. AQ.

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to beneficial microbes to develop novel living medicines, today announced the appointment of Antoine Awad as Head of Technical Operations, and the expansion of its manufacturing capabilities to produce clinical trial …

Analyst Keay Nakae of Chardan Capital reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $35.00. Keay Nakae’s Buy rating for Synlogic is rooted in several ...

In discussing Synlogic (NASDAQ: SYBX) stock, let’s begin with the upside because it’s substantial. SYBX shares carry an average target price of $7.17 yet trade for $0.65. They are therefore a ...Dec 15, 2022 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. Sell candidate since Nov 09, 2023 Gain 9.94% PDF. No changes to the price of Synlogic Inc stock on the last trading day (Friday, 17th Nov 2023). During the last trading day the stock fluctuated 16.23% from a day low at $1.91 to a day high of $2.22. The price has fallen in 5 of the last 10 days but is still up by 6.99% over the past 2 weeks.Sell candidate since Nov 09, 2023 Gain 9.94% PDF. No changes to the price of Synlogic Inc stock on the last trading day (Friday, 17th Nov 2023). During the last trading day the stock fluctuated 16.23% from a day low at $1.91 to a day high of $2.22. The price has fallen in 5 of the last 10 days but is still up by 6.99% over the past 2 weeks.Apr 28, 2023 · Synlogic (NASDAQ:SYBX) is undoubtedly a potential 10X investment, judging by its numbers alone. Shares of SYBX stock trade at only 53 cents per share, while its target stock price is $7.17 . CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).There’s still plenty of yield in the stock market even with the recent rally that has resulted in a 19% year-to-date gain in the this year.

SYBX shares carry an average target price of $7.17 yet trade for $0.65. They are therefore a 10X opportunity based on Wall Street consensus. The company reported a small amount of revenue in the ...Dec 15, 2022 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...SYBX Stock Performance Soars with 1,939.98% Increase: Analysts Predict Strong Growth for Synlogic Inc. SYBX stock had a significant performance on September 27, 2023. The 12-month price forecasts from three analysts for Synlogic Inc had a median target of $5.00, with a high estimate of $6.00 and a low estimate of $4.00.Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...

May 11, 2023 · CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ... ١٦‏/٠٥‏/٢٠١٧ ... ... stock ticker was the real bounty Synlogic sought. The companies expect to complete their deal sometime in the third quarter. The merged ...

We are driven by the promise of synthetic biology and by the new possibilities for better health that we believe we can bring to patients. Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease. The upgrade of Synlogic, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 Aug. 10: CI Science 37's Metasite ...According to 2 analysts, the average rating for SYBX stock is "Strong Buy." The 12-month stock price forecast is $82.5, which is an increase of 3,351.88% from the latest price.The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts. Mar 17, 2022 · Fourth Quarter 2021 Financial Results. As of December 31, 2021, Synlogic had cash, cash equivalents, and marketable securities of $136.6 million. Revenue was $0.6 million for the three months ... With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...

Find the latest Synlogic, Inc. (SYBX) stock quote, history, news and other vital information to help you with your stock trading and investing.

CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...

Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...Synlogic Announces Reverse Stock Split Sep 27 2023; SYBX:NAQ price moved over +9.73% to 2.31 Nov 22 2023; SYBX:NAQ price falls below 15-day moving average to 1.98 at 09:52 GMT Nov 24 2023; Key statistics. ... Synlogic, Inc. is a clinical-stage biopharmaceutical company.A high-level overview of Synlogic, Inc. (SYBX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Based upon its current operating plan and balance sheet as of December 31, 2022, Synlogic expects to have sufficient cash to be able to fund operations into the second half of 2024. About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria ...Synlogic, Inc. Common Stock (SYBX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price.Over the past week, Wood has been accumulating shares of Verve Therapeutics (VERV-6.12%) for her firm's flagship growth stock fund, the ARK Innovation ETF (ARKK 0.43%), and the biotech-focused ARK ...CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...

Nov 17, 2023 · Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout. Mar 29, 2023 · Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ... Formed in 2019, the Synlogic - Ginkgo collaboration is a five year, $30M strategic platform collaboration which accelerates expansion and development of Synlogic's pipeline of Synthetic Biotic ...Instagram:https://instagram. versus stockwhat is the most expensive car to insurebest dental insurencevanguard dividend schedule CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer. Mr. … blackrock global allocation fundmspr price First Quarter 2023 Financial Results. As of March 31, 2023, Synlogic had cash, cash equivalents and short-term investments of $57.4 million. Revenue was $0.2 million for each of the three months ... xpeng's The latest Synlogic stock prices, stock quotes, news, and SYBX history to help you invest and trade smarter.Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell, Ph.D., and Richard Shea. CAMBRIDGE, Mass. & AUSTIN, …